Relationship between Renin-Angiotensin System Blockers and Plasma Level of Adiponectin in Patients with Metabolic Syndrome
ZHAO Jiang
WU Yan
TIAN Fengshi
ZHAO Ziqin
LUO Rong
SHENG Jianmin
Abstract：Objective To explore the relationship between renin-angiotensin system (RAS) blockers and plasma lev-el of adiponectin (APN) in patients with metabolic syndrome (Mets). Methods Fifty-three patients with Mets were random-ized into control group (n=23), angiotensin-convertingenzyme inhibitor (ACEI) group (benidipine, 5 mg/d, n=15) and angio-tensinll recepter blockers(ARB)group (candesartan, 4 mg/d, n=15),and were given 4-week treatment. Twenty-three pa-tients, who were avoiding application related drugs affecting the RAS for four weeks, were used as control. The values of plas-ma APN, fasting blood glucose (FBG), fasting insulin (FINS), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), creatinine(CR), aspartate aminotransferase (ALT), bil-irubin (BIL) and insulin resistance index (HOMA-IR) were detected and compared before and after treatment. Results The levels of FBG and LDL-C were significantly decreased after treatment than those before treatment in ACEI group. The level of CR was significantly lower after treatment than that before treatment in ARB group (P<0.05). The plasma APN level was significantly higher after treatment compared to that before treatment in ACEI and ARB groups (P<0.01).There were no sig-nificant differences in the values of FINS,HOMA-IR,TC,ALT and BIL between 'before and after treatment' in three groups (P>0.05). The levels of CR, TC, ALT and BIL before treatment were influencing factors for the APN level. The levels of FBG and TC after treatment were influencing factors for the APN level. Conclusion APN may serve as potential therapeu-tic targets for treating Mets and its related complications by ACEI and ARB.
Keywords：renin-angiotensin systemangiotensin-converting enzyme inhibitorsadiponectinmetabolic syndrome Xreceptorangiotensintype 2angiotensinⅡtype 1 receptor blockers
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 968-970 )